{"id":"dara-iv","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Infusion-related reactions"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3121562","moleculeType":"Small molecule","molecularWeight":"784.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daratumumab targets CD38, a surface antigen highly expressed on multiple myeloma cells. Upon binding, it induces cell death through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). The IV formulation allows systemic delivery for treatment of hematologic malignancies.","oneSentence":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:37.386Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT06627309","phase":"","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-26","conditions":"Systemic AL Amyloidosis","enrollment":50},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT01665794","phase":"PHASE1, PHASE2","title":"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-08-13","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT03180736","phase":"PHASE3","title":"Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2017-06-14","conditions":"Multiple Myeloma","enrollment":304},{"nctId":"NCT01592370","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-08-02","conditions":"Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma","enrollment":320},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT04052880","phase":"PHASE2","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Larysa Sanchez","startDate":"2019-10-24","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":17},{"nctId":"NCT04558736","phase":"PHASE2","title":"Haploidentical HCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2021-01-21","conditions":"Aplastic Anemia, Bone Marrow Failure Syndrome","enrollment":21},{"nctId":"NCT03277105","phase":"PHASE3","title":"A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-27","conditions":"Multiple Myeloma","enrollment":522},{"nctId":"NCT03871829","phase":"PHASE2","title":"Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-31","conditions":"Multiple Myeloma","enrollment":88},{"nctId":"NCT04972942","phase":"PHASE1","title":"Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2023-05-22","conditions":"T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma","enrollment":30},{"nctId":"NCT04700176","phase":"PHASE2","title":"A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2022-05-02","conditions":"Multiple Myeloma","enrollment":1},{"nctId":"NCT04140162","phase":"PHASE2","title":"Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-10-05","conditions":"Multiple Myeloma","enrollment":57},{"nctId":"NCT06418477","phase":"PHASE2","title":"Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-06-15","conditions":"Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT06455748","phase":"NA","title":"Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study","status":"RECRUITING","sponsor":"Yongyong MA","startDate":"2024-03-01","conditions":"Amyloid Light-chain Amyloidosis","enrollment":20},{"nctId":"NCT04956302","phase":"PHASE1","title":"Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Abdullah Khan","startDate":"2021-09-27","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":1},{"nctId":"NCT03450057","phase":"PHASE2","title":"Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment","status":"COMPLETED","sponsor":"Hellenic Society of Hematology","startDate":"2018-02-15","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":38},{"nctId":"NCT02807454","phase":"PHASE2","title":"A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2016-07-07","conditions":"Multiple Myeloma","enrollment":37},{"nctId":"NCT02951819","phase":"PHASE2","title":"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-11-09","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT05054478","phase":"PHASE2","title":"Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10","conditions":"Plasma Cell Leukemia","enrollment":29},{"nctId":"NCT03000452","phase":"PHASE2","title":"A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-03-14","conditions":"Multiple Myeloma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JNJ-54767414"],"phase":"phase_3","status":"active","brandName":"Dara IV","genericName":"Dara IV","companyName":"Janssen Research & Development, LLC","companyId":"janssen-research-development-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Light chain myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}